佩拉戈尼丁-3-O-葡萄糖酸通过与circHMGCS1的相互作用恢复氧化的产生,以改善内皮功能障碍
Ming Zhang1, Guangyi Du1, Yang Xu1
1Department of Food Science and Nutrition, College of Biosystems Engineering and Food Science, Zhejiang University, Hangzhou 310058, China.
Journal of agricultural and food chemistry
|December 28, 2025
概括
佩拉尔戈尼丁-3-O-葡萄糖化物 (Pg3G) 是一种抗生素,通过向circHMGCS1.1,保护糖尿病血管功能障碍. 这项研究揭示了一种新型的安托西亚尼-circRNA机制,用于2型糖尿病的心血管保护.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 心血管研究研究心血管研究
背景情况:
- 心血管疾病 (CVD) 是2型糖尿病 (T2D) 死亡的主要原因,主要是由于血管内皮功能障碍.
- 安西氨酸显示出潜在的血管保护作用,但其精确的分子机制尚未完全理解.
研究的目的:
- 研究pelargonidin-3-O-glucoside (Pg3G) 在T2D中的血管保护作用和分子机制.
- 在内皮细胞和糖尿病模型中识别Pg3G的新分子标.
主要方法:
- 在高脂肪/高葡萄糖条件下使用内皮细胞进行体外试验.
- 在2型糖尿病小鼠体内研究.
- RNA测序和分子生物学技术用于识别circRNA目标.
- 分子对接和动力学模拟以评估化合物-RNA相互作用.
主要成果:
- 通过增强氧化 (NO) 生产,激活内皮氧化合成酶 (eNOS),减少活性氧物种 (ROS) 和抑制粘附分子,Pg3G恢复了内皮功能.
- 在糖尿病小鼠中,Pg3G改善了葡萄糖平衡和血管放松.
- Pg3G直接向并抑制了circHMGCS1,一种致病性循环RNA,从而重新激活了miR-4521/ARG1轴.
- 敲除circHMGCS1模仿了Pg3G的保护作用,而它的过度表达则逆转了它们.
结论:
- 佩拉戈尼丁-3-O-葡萄糖化物 (Pg3G) 在2型糖尿病中表现出显著的血管保护性.
- 鉴定出 circHMGCS1 是 Pg3G 的新型分子标,它对内皮功能产生有益作用.
- 这项研究揭示了一个独特的安托西亚尼-circRNA调节通路,对于糖尿病人血管保护至关重要.
相关概念视频
Nitric Oxide Signaling Pathway
6.1K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.1K
Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K
Antianginal Drugs: Nitrates and β-Blockers
1.3K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.3K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
527
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
527
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
435
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
435


